专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR102223105B1 분산안정화제로 폴리에틸렌글리콜계 고분자 및/또는 비닐피롤리돈계 고분자를 포함하는 타다라필 유리염기 함유 필름 제형 有权
公开(公告)号：KR102223105B1
公开(公告)日：2021-03-04
申请号：KR1020140043850
申请日：2014-04-11
申请人： 주식회사 씨티씨바이오
发明人： 전홍렬 , 권도우 , 이봉상 , 박수준 , 차봉근 , 김준기 , 한지영 , 길명철
IPC分类号： A61K9/70 , A61K47/34 , A61K47/30 , A61K31/4985
摘要： 본발명은타다라필유리염기를함유하는구강투여필름제제및 이의제조방법에관한것으로, 분산안정화제로폴리에틸렌글리콜계고분자및/또는비닐피롤리돈계고분자를첨가함으로써, 당업계에공지된여타의분산안정화제를사용했을때 발생할수 있는특유의향 또는맛을유발하지않고소량으로타다라필유리염기의필름내 분산안정도를극대화시킬수 있는효과가있으며, 타다라필유리염기입자의재응집현상이발생할가능성이극히낮은필름제공이가능할뿐만아니라, 제조공정중 기포의발생양도현저히감소시킬수 있다.

2. 发明授权

KR102026982B1 캡슐 충진 장치 有权
公开(公告)号：KR102026982B1
公开(公告)日：2019-09-30
申请号：KR1020180013559
申请日：2018-02-02
申请人： 주식회사 씨티씨바이오
发明人： 김승균 , 성윤진 , 이봉상 , 전홍렬
IPC分类号： A61J3/07 , A61K9/48

3. 发明授权

KR102005072B1 장관 세척용 하제 조성물 有权
公开(公告)号：KR102005072B1
公开(公告)日：2019-07-29
申请号：KR1020170173431
申请日：2017-12-15
申请人： 주식회사 씨티씨바이오
发明人： 전홍렬 , 이봉상 , 김현일 , 이한승
IPC分类号： A61K9/08 , A61K47/10 , A61K47/26 , A61K31/4402

4. 发明公开

KR1020160037530A 피페리딘-2,5-디온의 제조방법 및 이를 포함하는 약학적 조성물 审中-实审
标题翻译：哌啶-2,5-二酮的制备方法和包含其的药物组合物
公开(公告)号：KR1020160037530A
公开(公告)日：2016-04-06
申请号：KR1020140130211
申请日：2014-09-29
申请人： 주식회사 씨티씨바이오 , (주) 위디어
发明人： 조수연 , 민세혁 , 강필규 , 전홍렬 , 이봉상
IPC分类号： C07D211/86 , A61K31/4412 , A61P17/00
摘要： 본발명은피피리딘-2,5-디온(pipyridine-2,5-dione)의신규한제조방법및 피피리딘-2,5-디온의피부질환개선또는치료에대한용도에관한것으로약학적조성물또는화장료조성물로사용될수 있다. 본발명에따른피피리딘-2,5-디온은어떤 ALA 유도체보다안정성이뛰어나고, ALA의기능에는변함이없어피부질환등의치료에매우유용하게쓰일수 있다. 그리고본 발명에따른조성물은피부질환부위에국소적으로도포됨에따라더욱우수한치료효과를가지는바, 피부질환특히건선치료등 치유가쉽지않은질환치료제개발에유용하게활용할수 있다.
摘要翻译：本发明涉及一种制备管吡啶-2,5-二酮的新方法，以及用吡啶-2,5-二酮缓解或治疗药物组合物或化妆品组合物形式的皮肤病的新方法。根据本发明，管甲酰二酮-2,5-二酮比任何其他ALA衍生物具有更高的稳定性，并且不会改变ALA的功能，因此可用于治疗皮肤病等。此外，当将其局部施用于皮肤疾病部位时，根据本发明的组合物显示出更好的治疗效果。因此，该组合物可用于开发用于治疗难治性疾病如银屑病的药剂。

5. 发明公开

KR1020110045677A 올메사탄 유도체를 포함하는 고혈압 치료용 약학 조성물 有权
标题翻译：含有奥美沙坦衍生物的抗高血压药物组合物
公开(公告)号：KR1020110045677A
公开(公告)日：2011-05-04
申请号：KR1020090102347
申请日：2009-10-27
申请人： 주식회사 씨티씨바이오
发明人： 오창현 , 김정훈 , 유승원 , 전홍렬 , 권도우 , 이봉상 , 김현일 , 조영진 , 문지윤 , 이동진
IPC分类号： C07D403/10 , C07D403/08 , A61K31/4178 , A61P9/12
摘要： PURPOSE: A pharmaceutical composition containing olmesartan derivative for treating hypertension is provided to improve body absorption. CONSTITUTION: An olmesartan derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating hypertension or arteriosclerosis contains the olmesartan derivative of chemical formula 1 or pharmaceutically acceptable salt thereof. The compound has a hydrate or solvate form. The pharmaceutical composition is manufactured in the form of powders, granules, tablets, capsules, suppositories, solutions, suspensions, and emulsions.
摘要翻译：目的：提供含有治疗高血压的奥美沙坦衍生物的药物组合物，以改善身体吸收。构成：奥美沙坦衍生物由化学式1表示。用于预防或治疗高血压或动脉硬化的药物组合物含有化学式1的奥美沙坦衍生物或其药学上可接受的盐。该化合物具有水合物或溶剂化物形式。药物组合物以粉末，颗粒，片剂，胶囊，栓剂，溶液，悬浮液和乳液的形式制备。

6. 发明公开

KR1020090088564A 콜린 알포세레이트 함유 약학 제제 有权
标题翻译：含有胆固醇的药物制剂
公开(公告)号：KR1020090088564A
公开(公告)日：2009-08-20
申请号：KR1020080013922
申请日：2008-02-15
申请人： 주식회사 씨티씨바이오
发明人： 박수준 , 이봉상 , 권도우 , 전홍렬
IPC分类号： A61K9/16 , A61K9/14 , A61K31/27
CPC分类号： A61K31/685 , A61K9/16 , A61K9/1611 , A61K9/167 , A61K9/1694
摘要： A pharmaceutical preparation containing a choline alfoscerate is provided to easily produce the preparation using colloidal silicon dioxide and water-soluble polymer. A pharmaceutical preparation containing a choline alfoscerate comprises the choline alfoscerate in which colloidal silicon dioxide is absorbed. The choline alfoscerate absorbs to 0.5-1.5wt.pt. of colloidal silicon dioxide. A method for producing the pharmaceutical preparation containing choline alfoscerate comprises: a step of absorbing the choline alfoscerate to colloidal silicon dioxide; and a step of producing a granule using a colloidal silicon dioxide with hydroxypropylmethylcellulose, polyvinylpyrrolidone or their mixture.
摘要翻译：提供含有胆碱烯丙酯的药物制剂，以容易地制备使用胶体二氧化硅和水溶性聚合物的制剂。含有α-胆碱酯的药物制剂含有胶体二氧化硅被吸收的胆碱糠醛。胆碱脂肪酸可吸收至0.5-1.5wt.pt。的胶体二氧化硅。一种含有胆碱α-肌酸酯的药物制剂的制造方法，其特征在于，含有将胆碱酯化成胶体二氧化硅的步骤; 以及使用胶体二氧化硅与羟丙基甲基纤维素，聚乙烯吡咯烷酮或它们的混合物制备颗粒的步骤。

7. 发明公开

KR1020090033000A 에소메프라졸 함유 약학 조성물 有权
标题翻译：含有异喹诺酮的药物组合物
公开(公告)号：KR1020090033000A
公开(公告)日：2009-04-01
申请号：KR1020080090692
申请日：2008-09-16
申请人： 주식회사 씨티씨바이오
发明人： 이봉상 , 권도우 , 전홍렬 , 곽성신 , 문지윤 , 이동진
IPC分类号： A61K9/14 , A61K31/44 , A61K47/30
CPC分类号： A61K31/4439 , A61K9/1611 , A61K9/2009
摘要： Provided is a pharmaceutical composition containing esomeprazole free base or alkaline salts thereof wherein the esomeprazole has improved stability for treating and preventing peptic ulcer and reflux oesophagitis as a proton pump inhibitor. A pharmaceutical composition containing esomeprazole includes solid-dispersion comprising esomeprazole free base or alkaline salts thereof, alkalizer, polyvinylpyrrolidone and vinylpyrrolidone-vinyl acetate copolymer. The alkalizer indicates MgO or Mg(OH)2. A method for producing the pharmaceutical composition containing esomeprazole consists of the following steps of: preparing a solution or suspension containing esomeprazole free base or alkaline salts thereof, magnesium oxide or magnesium hydroxide, polyvinylpyrrolidone, and vinylpyrrolidone-vinyl acetate copolymer; and drying the prepared solution or suspension.
摘要翻译：提供含有艾美拉唑游离碱或其碱式盐的药物组合物，其中艾美拉唑具有改善的稳定性，用于治疗和预防作为质子泵抑制剂的消化性溃疡和反流性食管炎。含有艾美拉唑的药物组合物包括含有埃索美拉唑游离碱或其碱式盐，碱化剂，聚乙烯吡咯烷酮和乙烯基吡咯烷酮 - 乙酸乙烯酯共聚物的固体分散体。碱化剂表示MgO或Mg（OH）2。制备含有艾美拉唑的药物组合物的方法包括以下步骤：制备含有艾美拉唑游离碱或其碱式盐，氧化镁或氢氧化镁，聚乙烯吡咯烷酮和乙烯基吡咯烷酮 - 乙酸乙烯酯共聚物的溶液或悬浮液; 并干燥制备的溶液或悬浮液。

8. 发明公开

KR1020080028365A 메실산독사조신 서방정의 제조방법 有权
标题翻译：含有二氧化铬甲磺酸盐的控释片材的制造方法
公开(公告)号：KR1020080028365A
公开(公告)日：2008-03-31
申请号：KR1020077028790
申请日：2006-05-30
申请人： 주식회사 씨티씨바이오
发明人： 전홍렬 , 이봉상 , 유세근 , 김현일
IPC分类号： A61K9/22 , A61K9/20 , A61K31/517
CPC分类号： A61K9/2054 , A61K9/205
摘要： A method for preparing a controlled-release tablet comprising doxazosin mesylate is provided to be simple and economical, and obtain the controlled-release tablet which releases doxazosin mesylate at zero-order rate for 12 hours and has reduced content variation and dissolution variation. A method for preparing a controlled-release tablet comprising doxazosin mesylate comprises the steps of: (a) mixing doxazosin mesylate, low- viscosity hydroxypropylmethylcellulose, at least one gum selected from the group consisting of xanthan gum, arabia gum, guar gum and locust bean gum, a diluent and a lubricant; (b) compacting the mixture to prepare dry granule; and (c) mixing the dry granule with a lubricant to make a final mixture and tabletting the final mixture, wherein the viscosity of the low-viscosity hydroxypropylmethylcellulose is between 80 and 120 cP when measured as 2 wt% aqueous solution at a temperature of 20 deg.C and the diluent is at least one selected from the group consisting of lactose, mannitol, microcrystalline cellulose and corn starch.
摘要翻译：提供了包含甲磺酸多沙唑嗪的控释片的制备方法简单经济，得到以零级速率释放甲磺酸多沙唑嗪12小时并具有降低的含量变化和溶解变化的控释片。制备包含甲磺酸多沙唑嗪的控释片剂的方法包括以下步骤：（a）混合甲磺酸多沙唑嗪，低粘度羟丙基甲基纤维素，至少一种选自黄原胶，阿拉伯胶，瓜尔胶和刺槐豆的口香糖胶，稀释剂和润滑剂; （b）压实混合物以制备干燥颗粒; 和（c）将干燥颗粒与润滑剂混合以制成最终混合物并对最终混合物进行压片，其中当在20℃的温度下测量为2重量％水溶液时，低粘度羟丙基甲基纤维素的粘度为80至120cP 并且稀释剂是选自乳糖，甘露醇，微晶纤维素和玉米淀粉中的至少一种。

9. 发明授权

KR100684099B1 클로피도그렐 유리염기 함유 조성물 有权
标题翻译：含氯吡格雷游离碱的成分
公开(公告)号：KR100684099B1
公开(公告)日：2007-02-16
申请号：KR1020050058337
申请日：2005-06-30
申请人： 주식회사 씨티씨바이오
发明人： 전홍렬 , 이봉상 , 권도우 , 오세흠 , 유세근 , 오동윤 , 김현일
IPC分类号： A61K31/44 , A61K47/00 , A61K9/00 , A61P9/10
摘要： 본 발명은 클로피도그렐 유리염기를 함유하는 조성물에 관한 것으로서, 본 발명은 클로피도그렐 유리염기, 산 및 약학적으로 허용가능한 부형제를 함유하는 것을 특징으로 하는 클로피도그렐 유리염기 함유 조성물을 제공한다. 본 발명의 조성물은 pH가 높은 매질에서도 용출률이 좋을 뿐만 아니라 안정성이 뛰어나다.
클로피도그렐 유리염기, 산, 항산화제, 고체분산체

10. 发明公开

KR1020020063978A 장용성 유산균 미세과립 조성물 및 이의 제조방법 无效
标题翻译：肠道酸性细菌微生物组成及其生产
公开(公告)号：KR1020020063978A
公开(公告)日：2002-08-07
申请号：KR1020010004516
申请日：2001-01-31
申请人： 전홍렬 , 주식회사 씨티씨바이오
发明人： 전홍렬
IPC分类号： A61K9/16
CPC分类号： A61K9/5036 , A61K9/1652 , A61K35/744
摘要： PURPOSE: A microgranular composition obtained by mixing lactic acid bacteria, a mucosa-adherent polymer and an excipient or coating the mixture as a seed with a special water-based coating base is provided. Whereby, the death rate(or death ratio) of lactic acid bacteria is reduced in the process for manufacturing coating granules and the lactic acid bacteria are stably protected from gastric acid and bile acid. CONSTITUTION: This composition contains: a seed including 10 to 90% by weight of lactic acid bacteria, 1 to 80% by weight of a mucosa-adherent polymer and 1 to 80% by weight of an excipient; and a water-based coating layer formed from 1 to 80% by weight of a water-based coating base material, based on the total weight of the seed. The lactic acid bacteria are one or more selected from the group consisting of Streptococcus, Lactococcus, Leuconostoc, Pediococcus, Enterococcus, Lactobacillus and Bifidobacterium.
摘要翻译：目的：提供通过混合乳酸菌，粘膜粘附聚合物和赋形剂或将混合物作为种子涂覆有特殊的水基涂层而获得的微粒组合物。因此，在制造涂层颗粒的过程中乳酸菌的死亡率（或死亡率）降低，并且乳酸菌被稳定地保护免于胃酸和胆汁酸。构成：该组合物包含：包含10〜90重量％的乳酸菌，1〜80重量％的粘膜粘附性聚合物和1〜80重量％的赋形剂的种子; 以及基于种子的总重量，由水性涂料基材1〜80重量％形成的水性涂层。乳酸菌是选自链球菌属，乳球菌属，明串珠菌属，扁球菌属，肠球菌属，乳杆菌属和双歧杆菌属中的一种或多种。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式